Topical review: studies on management of myopia progression from 2019 to 2021
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.21/15154 |
Resumo: | Myopia is a common eye condition that increases the risk of sight-threatening complications. Each additional diopter increases the chance of complications. The purpose of this review is to make an overview of myopia control treatment options for children with myopia progression. In this non-systematic review, we searched PubMed and Cochrane databases for English-language studies published from 2019 through September 2021. Emphasis was given to a selection of randomized controlled trials. Nineteen randomized controlled trials and two retrospective studies were included. Topical atropine and orthokeratology remain the most used treatments, while lenses with novel designs are emerging treatments. Overall myopia progression in the treatment groups for low-dose atropine and orthokeratology were lower than in the control groups and their efficacy was reported in several randomized controlled trials and confirmed by various systematic reviews and meta-analysis. The findings of myopia progression and axial elongation for the MiSight, defocus incorporated multiple segments spectacle lens, highly aspherical lenslets and diffusion optics technology spectacle lens was comparable. Public health interventions to optimize environmental influences may also be important strategies to control myopia. The optimal choice of management of myopia depends on treatment availability, acceptability to the child and parents, and specific patient features such as age, baseline myopia, and lifestyle. Eye care providers need to understand the advantages and disadvantages of each therapy to best counsel parents of children with myopia. |
id |
RCAP_ba3b2555abd2504cc592f414c468f92e |
---|---|
oai_identifier_str |
oai:repositorio.ipl.pt:10400.21/15154 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Topical review: studies on management of myopia progression from 2019 to 2021OphthalmologyMyopiaChildrenNon-systematic reviewMyopia is a common eye condition that increases the risk of sight-threatening complications. Each additional diopter increases the chance of complications. The purpose of this review is to make an overview of myopia control treatment options for children with myopia progression. In this non-systematic review, we searched PubMed and Cochrane databases for English-language studies published from 2019 through September 2021. Emphasis was given to a selection of randomized controlled trials. Nineteen randomized controlled trials and two retrospective studies were included. Topical atropine and orthokeratology remain the most used treatments, while lenses with novel designs are emerging treatments. Overall myopia progression in the treatment groups for low-dose atropine and orthokeratology were lower than in the control groups and their efficacy was reported in several randomized controlled trials and confirmed by various systematic reviews and meta-analysis. The findings of myopia progression and axial elongation for the MiSight, defocus incorporated multiple segments spectacle lens, highly aspherical lenslets and diffusion optics technology spectacle lens was comparable. Public health interventions to optimize environmental influences may also be important strategies to control myopia. The optimal choice of management of myopia depends on treatment availability, acceptability to the child and parents, and specific patient features such as age, baseline myopia, and lifestyle. Eye care providers need to understand the advantages and disadvantages of each therapy to best counsel parents of children with myopia.Wolters KluwerRCIPLLança, CarlaRepka, Michael X.Grzybowski, Andrzej2023-012023-01-01T00:00:00Z2024-12-15T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.21/15154engLança CC, Repka MX, Grzybowski A. Topical review: studies on management of myopia progression from 2019 to 2021. Optom Vis Sci. 2023;100(1):23-30.10.1097/OPX.0000000000001947info:eu-repo/semantics/embargoedAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-03T10:12:19Zoai:repositorio.ipl.pt:10400.21/15154Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:22:52.207767Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Topical review: studies on management of myopia progression from 2019 to 2021 |
title |
Topical review: studies on management of myopia progression from 2019 to 2021 |
spellingShingle |
Topical review: studies on management of myopia progression from 2019 to 2021 Lança, Carla Ophthalmology Myopia Children Non-systematic review |
title_short |
Topical review: studies on management of myopia progression from 2019 to 2021 |
title_full |
Topical review: studies on management of myopia progression from 2019 to 2021 |
title_fullStr |
Topical review: studies on management of myopia progression from 2019 to 2021 |
title_full_unstemmed |
Topical review: studies on management of myopia progression from 2019 to 2021 |
title_sort |
Topical review: studies on management of myopia progression from 2019 to 2021 |
author |
Lança, Carla |
author_facet |
Lança, Carla Repka, Michael X. Grzybowski, Andrzej |
author_role |
author |
author2 |
Repka, Michael X. Grzybowski, Andrzej |
author2_role |
author author |
dc.contributor.none.fl_str_mv |
RCIPL |
dc.contributor.author.fl_str_mv |
Lança, Carla Repka, Michael X. Grzybowski, Andrzej |
dc.subject.por.fl_str_mv |
Ophthalmology Myopia Children Non-systematic review |
topic |
Ophthalmology Myopia Children Non-systematic review |
description |
Myopia is a common eye condition that increases the risk of sight-threatening complications. Each additional diopter increases the chance of complications. The purpose of this review is to make an overview of myopia control treatment options for children with myopia progression. In this non-systematic review, we searched PubMed and Cochrane databases for English-language studies published from 2019 through September 2021. Emphasis was given to a selection of randomized controlled trials. Nineteen randomized controlled trials and two retrospective studies were included. Topical atropine and orthokeratology remain the most used treatments, while lenses with novel designs are emerging treatments. Overall myopia progression in the treatment groups for low-dose atropine and orthokeratology were lower than in the control groups and their efficacy was reported in several randomized controlled trials and confirmed by various systematic reviews and meta-analysis. The findings of myopia progression and axial elongation for the MiSight, defocus incorporated multiple segments spectacle lens, highly aspherical lenslets and diffusion optics technology spectacle lens was comparable. Public health interventions to optimize environmental influences may also be important strategies to control myopia. The optimal choice of management of myopia depends on treatment availability, acceptability to the child and parents, and specific patient features such as age, baseline myopia, and lifestyle. Eye care providers need to understand the advantages and disadvantages of each therapy to best counsel parents of children with myopia. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-01 2023-01-01T00:00:00Z 2024-12-15T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.21/15154 |
url |
http://hdl.handle.net/10400.21/15154 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Lança CC, Repka MX, Grzybowski A. Topical review: studies on management of myopia progression from 2019 to 2021. Optom Vis Sci. 2023;100(1):23-30. 10.1097/OPX.0000000000001947 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/embargoedAccess |
eu_rights_str_mv |
embargoedAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Wolters Kluwer |
publisher.none.fl_str_mv |
Wolters Kluwer |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133500613328896 |